About us
Our group of scientists and clinicians translate new understanding of tumour B-cell biology into clinical practice. We investigate how the structure and function of the key driver, the B-cell receptor (BCR), influences the development of B-cell cancers and how it can be tackled with new therapies.
We have contributed to the definition of the aggressive and indolent subsets of chronic lymphocytic leukaemias (CLL) and the development of BCR-associated kinase inhibitors, now a main treatment for CLL patients.
Our most recent investigations have also expanded around the cancer-specific post-translation modifications (oligomannose-type glycans) occupying the antigen-binding regions of the BCR of follicular lymphomas and how to target them therapeutically with monoclonal antibodies.
We are committed to:
- understanding these and other B cell cancers (also including HCL, SMZL and DLBCL).
- improving the outcomes and quality of life of the patients affected by them.
- training and mentoring the next generation of cancer researchers.
Professor Forconi’s patient-centric research has the potential to demonstrate the significant impact on treatment efficiency and patient well-being, while also alleviating pressures on the healthcare system. Leukaemia UK is proud to support his work to deliver compassionate, tailored care to those facing CLL and we hope this project will inspire further advancements in leukaemia treatment and patient quality of life.
Dr Simon Ridley
Director of Research and Advocacy at Leukaemia UK